Chinese pharmaceutical company Huapont Life Sciences has announced plans to acquire 48.3% stake in a local tourist firm from a controlling shareholder.
Huapont is engaged in manufacturing and marketing active pharmaceutical ingredients (APIs) and finished doses.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The acquisition will involve a purchase consideration of ¥139.4m ($21.47m).
Sosei Group has reached an agreement to acquire 25.6% stake in MiNA Therapeutics, and an option to acquire further defined stakes to eventually fully acquire the target company.
The purchase consideration for the 25.6% stake acquisition is £35m ($45.2m). A further £140m ($180.83m) is payable in the event of 100% acquisition, as part of the agreement.
The target company’s shareholders could further receive up to £240m ($310m) upon achievement of development and regulatory milestones.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
